TABLE 3:
Best response for patients with measurable disease.
|
|
|
|
|
|---|---|---|---|
| Temozolomide + Irinotecan |
Temozolomide + Irinotecan - Bevacizumab |
||
| Characteristics |
Categories |
N (%) |
N (%) |
| Best Response | Complete response | 0 (0.0) | 8 (17.4) |
| Non-responder | 2 (4.2) | 1 (2.2) | |
| Progressive disease | 16 (33.3) | 6 (13.0) | |
| Partial response | 16 (33.3) | 14 (30.4) | |
| Stable disease | 14 (29.2) | 17 (37.0) | |